Meeting
2016 Gastrointestinal Cancers Symposium
Predictive value of ERCC1 and KRAS in colorectal cancer patients with FOLFOX chemotherapy.
Authors
In Kyu Lee
The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, South Korea
In Kyu Lee , Sung-Bong Choi , DaeYoung Cheung , Jin Il Kim
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Translational Research
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr 588)
DOI
10.1200/jco.2016.34.4_suppl.588
Abstract #
588
Poster Bd #
E15
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
Anti-KRAS siRNA nanoparticles for targeted colorectal cancer therapy.
First Author: Bradley Krasnick
Poster
2015 ASCO Annual Meeting
ERCC1 induction after oxaliplatin exposure may depend on KRAS mutational status in colorectal cancer patient: preliminary data from liquid biopsy.
First Author: Mariantonietta Di Salvatore
Poster
2019 Gastrointestinal Cancers Symposium
Small bowel adenocarcinoma: A single center experience.
First Author: Lindsay Marie Hannan
Poster
2015 Gastrointestinal Cancers Symposium
Awareness of KRAS testing by oncologists and panitumumab use in colorectal cancer patients: A European survey.
First Author: Jorg Trojan